Showing 1351-1360 of 6664 results for "".
DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourPanel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launcJournal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).Noah Worcester 2024: Dr. Hinshaw on Onychomycosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-hinshaw-onychomycosis/24587/Molly Hinshaw, MD, FAAD, summarizes her lecture on diagnosis and management of onychomycosis at the 2024 Noah Worcester Dermatological Society meeting.CSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.The Skin Science Podcast: Episode 1 - "The Skin Microbiome" with Doris Day, MD, FAAD, MA
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-skin-science-podcast-episode-1-the-skin-microbiome-with-doris-day-md-faad-ma/20067/Hosted by Thomas Hitchcock, Ph.D., Chief Science Officer at Crown Laboratories, The Skin Science Podcast is a monthly podcast that covers topics relating to skin health. The series will dig into hot topics within dermatology and aesthetics and will challenge the audience to think a bit differently aRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss thePsoriasis Comorbidities: Assessing Risks and the Role of Dermatologists
https://practicaldermatology.com/topics/psoriasis/psoriasis-comorbidities-assessing-risks-and-the-role-of-dermatologists-/18242/Ronald Prussick, MD discusses the most common comorbidities of psoriasis and the risks patients have for cardiovascular issues, depression, fatty liver disease, vitamin D deficiency, and more. He talks to host Nancy Samolitis, MD about the role dermatologists play in assessing and treating these risBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentThe Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.